Five Prime Therapeutics Inc  

(Public, NASDAQ:FPRX)   Watch this stock  
Find more results for FPRX
20.05
-0.84 (-4.02%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 19.73 - 21.15
52 week 19.73 - 53.89
Open 21.00
Vol / Avg. 2.50M/915,331.00
Mkt cap 580.05M
P/E     -
Div/yield     -
EPS -5.07
Shares 28.93M
Beta 3.90
Inst. own 86%
Dec 14, 2017
Five Prime Therapeutics Inc at BMO Capital Markets Prescriptions for Success Healthcare Conference
Nov 11, 2017
Five Prime Therapeutics Inc Review Cabiralizumab Phase 1a/1b Data Call
Nov 8, 2017
Five Prime Therapeutics Inc Review Cabiralizumab Phase 1a/1b Data Call - Webcast
Nov 6, 2017
Q3 2017 Five Prime Therapeutics Inc Earnings Call - Webcast
Sep 28, 2017
Five Prime Therapeutics Inc at Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -519.40% -214.06%
Operating margin -528.91% -323.26%
EBITD margin - -317.58%
Return on average assets -47.08% -13.18%
Return on average equity -56.98% -15.93%
Employees 195 -
CDP Score - -

Address

2 Corporate Dr
SOUTH SAN FRANCISCO, CA 94080-7047
United States - Map
+1-415-3655600 (Phone)
+1-415-3655601 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.

Officers and directors

Lewis T. Williams M.D. Ph.D. Executive Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Marc L. Belsky Chief Financial Officer, Senior Vice President
Age: 61
Bio & Compensation  - Reuters
Aron Marc Knickerbocker MBA President, Chief Executive Officer, Chief Operating Officer, Director
Age: 47
Bio & Compensation  - Reuters
Kevin Baker Ph.D. Senior Vice President, Development Sciences
Age: 56
Bio & Compensation  - Reuters
Helen Louise Collins M.D. Senior Vice President and Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
Francis Willard Sarena J.D. Chief Strategy Officer and Secretary
Age: 46
Bio & Compensation  - Reuters
Mark D. McDade Lead Independent Director
Age: 61
Bio & Compensation  - Reuters
Garry Nicholson Director
Bio & Compensation  - Reuters
Franklin M. Berger Independent Director
Age: 67
Bio & Compensation  - Reuters
Fred E. Cohen Ph.D. M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters